11 unchanged sentences
(incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K (001-36352 ) , filed on June 9, 2020 ) .
+Added: 3.3* Certificate of Amendment of Ninth Amended and Restated Certificate of Incorporation of Akebia Therapeutics, Inc.
3.4 Second Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K (001-36352), filed on April 28, 2023) .
−Removed: 180 CityPoint Waltham, Massachusetts Lease Agreement Between BP Third Avenue LLC and Akebia Therapeutics, Inc.
−Removed: dated January 27, 2026 ( incorporated by reference to Exhibit 10.1 0 to the Company's Annual Report on Form 10-K (001-36352) , filed on February 26, 2026).
−Removed: Akebia Therapeutics, Inc.
−Removed: Fifth Amended and Restated Non-Employee Director Compensation Program, effective January 26, 2026 (incorporated by reference to Exhibit 10.11 to the Company's Annual Report on Form 10-K (001-36352), filed on February 26, 2026).
−Removed: Amended and Restated Executive Severance Agreement, dated January 28, 2026, between Akebia Therapeutics, Inc.
−Removed: Butler (incorporated by reference to Exh ibit 99.1 to the Company's Current Report on Form 8-K (001-36352), filed on January 30, 2026 ) .
−Removed: Amended and Restated Executive Severance Agreement, dated January 28, 2026, between Akebia Therapeutics, Inc.
−Removed: Ostrowski (incorporated by reference to Exhibit 99.
−Removed: 2 to the Company's Current Report on Form 8-K (001-36352), filed on January 30, 2026) .
−Removed: 2 026 Form of Executive Severance Agreement for Non-CEO C-Level Executives (incorporated by reference to Exhibit 10.16 to the Company's Annual Report on Form 10-K (001-36352 ) , filed on February 26, 2026).
−Removed: Form of Officer Restricted Stock Unit Agreement under 2023 Stock Incentive Plan (Reflecting C-Level ESA Terms and Clawback Policy) (incorporated by reference to Exhibit 10.42 to the Company's Annual Report on Form 10-K (001-36352), filed on February 26, 2026 ).
−Removed: Form of Officer Stock Option Agreement under 2023 Stock Incentive Plan (Reflecting C-Level ESA Terms and Clawback Policy) (incorporated by reference to Exhibit 10.4 3 to the Company's Annual Report on Form 10-K (001-36352), filed on February 26, 2026).
−Removed: Form of Officer Restricted Stock Agreement under 2023 Stock Incentive Plan (Reflecting C-Level ESA Terms) (incorporated by reference to Exhibit 10.4 4 to the Company's Annual Report on Form 10-K (001-36352), filed on February 26, 2026).
−Removed: Form of Officer Stock Option Agreement under 2023 Stock Incentive Plan (Reflecting C-Level ESA Terms) (incorporated by reference to Exhibit 10.4 5 to the Company's Annual Report on Form 10-K (001-36352), filed on February 26, 2026).
+Added: 10.1* Eight Amendment to Lease between CLPF-Cambridge Science Center, LLC and Akebia Therapeutics, Inc., dated April 7, 2026.
+Added: 10.2* Amendment # 4, effective as of April 28, 2026, to Supply Agreement, dated as of April 2, 2020, by and between Akebia Therapeutics, Inc.
+Added: and STA Pharmaceutical Hong Kong Limited.
+Added: 10.3* Amendment # 2, effective as of April 28, 2026, to Supply Agreement, dated as of February 10, 2021, by and between Akebia Therapeutics, Inc.
+Added: and STA Pharmaceutical Hong Kong Limited.
31.1* Certification of Principal Executive Officer Required Under Rule 13a-14(a) of the Securities Exchange Act of 1934, as amended.
2 unchanged sentences
101.INS* Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document)
−Removed: Akebia Therapeutics, Inc.
−Removed: | Form 10-Q | Page 109
101.SCH* Inline XBRL Taxonomy Extension Schema Document
5 unchanged sentences
* Filed, or submitted electronically, herewith
−Removed: † Indicates management contract or compensatory plan
−Removed: Indicates portions of the exhibit (indicated by asterisks) have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K
Akebia Therapeutics, Inc.
2 unchanged sentences
AKEBIA THERAPEUTICS, INC.
+Added: August 5, 2026
President and Chief Executive Officer
(Principal Executive Officer)
+Added: August 5, 2026
Senior Vice President, Chief Financial Officer, Chief Business Officer and Treasurer
(Principal Financial Officer)
+Added: August 5, 2026
/s/ Richard C.
Senior Vice President, Chief Accounting Officer (Principal Accounting Officer)
−Removed: Akebia Therapeutics, Inc.
−Removed: | Form 10-Q | Page 111
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.